|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 4800 Deerwood Campus Parkway (DCC 2-2) |
Address2 |
|
| City | Jacksonville |
State | FL |
Zip Code | 32246 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6382-12
|
||||||||
|
6. House ID# 314000000
|
||||||||
| TYPE OF REPORT | 8. Year | 2021 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kelly James |
Date | 7/16/2021 10:10:46 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Affordable Care Act (ACA); ACA Reform; ACA Coverage Improvement; Health Reform; Lower Health Care Costs; Transparency; Surprise Billing; Maternal Health; COVID-19 Response/Relief Packages; Telehealth/Audio-Only; COVID-19; Black Maternal Health; Age Adjustment; Health Disparities; Implementation Timetables/Deliverables; Health Equities; SEP; Modeling of BCBSA Individual Market Proposals; CAA; APCD; Closing Coverage Gap; Extending Exchange Subsidies; Health Equity Issues
HR 133 (116th Congress), Consolidated Appropriations Act, 2021, by Rep. Henry Cuellar (D-TX). A spending package that includes a $1.4 trillion to fund the federal government through September 30, 2021, $900 billion in funding for COVID-19 relief, protections for patients from surprise medical bills and a number of other health-related provisions.
HR 19 (117th Congress), Lower Costs, More Cures Act of 2021, by Rep. Cathy McMorris Rodgers (R-WA). Provides for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration.
HR 1319 (117th Congress), American Rescue Plan Act of 2021, by Rep. John Yarmuth (D-KY). Provides additional relief to address the continued impact of COVID-19 (i.e., coronavirus disease 2019) on the economy, public health, state and local governments, individuals, and businesses.
HR 2503 (117th Congress), Social Determinants Accelerator Act of 2021, by Rep. Cheri Bustos (D-IL). To direct the Secretary of Health and Human Services to establish an interagency council on social determinants of health.
HR 3969 (117th Congress), by Rep. John Curtis (R-UT). To amend title XXVII of the Public Health Service Act to include activities to address social determinants of health in the calculation of medical loss ratios.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), White House Office, Executive Office of the President (EOP), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
Giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicaid Maternal Health; Medicaid; Medicare Advantage Audio Only; Medicare; Medicare Advantage Reform; Part D Reform
HR 7659 (116th Congress), Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, by Rep. Terri Sewell (D-AL). Requires the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans.
HR 1868 (117th Congress), by Rep. John Yarmuth (D-KY). Makes several budgetary and technical changes to provisions under Medicare and Medicaid, including continuing to exempt Medicare from sequestration until December 31, 2021.
HR 2166 (117th Congress), by Rep. Terri Sewell (D-AL). Amends title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans and PACE programs, and for other purposes.
HR 2170 (117th Congress), HAPI Act, by Rep. Darren Soto (D-FL). Amends title XIX of the Social Security Act to improve access to adult vaccines under Medicaid.
HR 2815 (117th Congress), BIOSIM Act, by Rep. Kurt Schrader (D-OR). Amends title XVIII of the Social Security Act to provide for a temporary payment increase under the Medicare program for certain biosimilar biological products to encourage the development and use of such products.
HR 2846 (117th Congress), Ensuring Access to Lower Cost Medicines for Seniors Act of 2021, by Rep. David McKinley (R-WV). Amends title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary.
S 4840 (116th Congress), Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, by Sen. Pat Roberts (R-KS). Allows audio-only diagnoses made via telehealth to be used for purposes of determining risk adjustments to payments under Medicare Advantage, and requires payments for Medicare telehealth services furnished during the public health emergency relating to COVID-19 to be made in the same amounts as those for in-person services.
S 150 (117th Congress), Ensuring Parity in MA for Audio-Only Telehealth Act of 2021, by Sen. Catherine Cortez Masto (D-NV). Amends title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
Giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
COVID-19 Testing; COVID-19 Vaccine Strategy and Treatment; Vaccine Rollout; Rx Reform; Prescription Drugs; Prescription Drug Reform
HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees.
HR 550 (117th Congress), Immunization Infrastructure Modernization Act of 2021, by Rep. Ann Kuster (D-NH). Amends the Public Health Service Act with respect to immunization system data modernization and expansion.
HR 951 (117th Congress), Maternal Vaccination Act, by Rep. Terri Sewell (D-AL). Directs the Secretary of Health and Human Services to carry out a national campaign to increase awareness of the importance of maternal vaccinations for the health of pregnant and postpartum individuals and their children.
HR 979 (117th Congress), Vaccine Fairness Act, by Rep. Angie Craig (D-MN). Directs the Secretary of Health and Human Services to submit to Congress a weekly report on COVID-19 vaccine distribution.
HR 1452 (117th Congress), by Rep. Dan Crenshaw (R-TX). Directs the Secretary of Health and Human Services to publish the formula the Secretary uses to determine the allocation of COVID-19 vaccines.
HR 1978 (117th Congress), Protecting Seniors Through Immunization Act of 2021, by Rep. Ann Kuster (D-NH). Amends title XVIII of the Social Security Act to provide information regarding vaccines for seniors as part of the Medicare & You handbook and to ensure that the treatment of cost sharing for vaccines under Medicare Part D is consistent with the treatment of vaccines under Medicare Part B.
HR 2347 (117th Congress), Strengthening the Vaccines for Children Program Act of 2021, by Rep. Kim Schrier (D- WA). Amends title XIX of the Social Security Act to ensure adequate access to vaccines under the Medicaid program and the Vaccines for Children program.
HR 2831 (117th Congress), Prompt Approval of Safe Generic Drugs Act, by Rep. Nanette Diaz Barragan (D-CA). Amends the Federal Food, Drug, and Cosmetic Act to provide for the prompt approval of drugs when safety information is added to labeling.
HR 3013 (117th Congress), COVID Vaccine Transportation Access Act, by Rep. Nanette Diaz Barragan (D-CA). Authorizes the Secretary of Health and Human Services to award grants for removing transportation barriers to accessing vaccines for SARS-CoV-2, including booster vaccines, for individuals from low-income communities, minority communities, or other communities in which transportation poses a barrier to health care access.
HR 3655 (117th Congress), Vaccine Injury Compensation Modernization Act of 2021, by Rep. Lloyd Doggett (D-TX). Amends the Public Health Service Act to make updates to the Vaccine Injury Compensation Program.
HR 3742 (117th Congress), Vaccine INFO Act, by Rep. Gus Bilirakis (R-FL). Requires the Secretary of Health and Human Services to issue revised regulations to require the dissemination of information on ACIP recommended immunizations to staff of nursing facilities.
HR 3743 (117th Congress), Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act, by Rep. Richard Hudson (R-NC). Increases funding for the Reagan-Udall Foundation for the Food and Drug Administration and for the Foundation for the National Institutes of Health.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
Giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
ACA Tax Credits; APTC
HR 1868 (117th Congress), by Rep. John Yarmuth (D-KY). Makes several budgetary and technical changes to provisions under Medicare and Medicaid, including continuing to exempt Medicare from sequestration until December 31, 2021.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
Giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |